AmpliMed Reports Results From AMP-019; A Randomized Double Blind Trial Of Gemcitabine/Placebo Vs. Gemcitabine/Amplimexon In Advanced Pancreatic Cancer

Links shared publicly online about this topic.

  • 1,027
    total visits

AmpliMed Reports Results From AMP-019; A Randomized Double Blind Trial Of Gemcitabine/Placebo Vs. Gemcitabine/Amplimexon In Advanced Pancreatic Cancer

medicalnewstoday.com —

AmpliMed Corporation, a cancer therapeutics company, announced results from AMP-019, a randomized double-blind, placebo-controlled Phase II screening trial designed to determine if a Phase III tri

View full resource at medicalnewstoday.com

Tags: Pancreatic Disease, Cancer, Pancreatic Cancer, Blindness

  • Share

Most Recently Shared on July 12, 2010 at 8:04 pm By:

mnt_cancer MNT Cancer News

AmpliMed Reports Results From AMP-019; A Randomized Double Blind Trial Of Gemcitabine/Placebo Vs. Gemcitabine/Amplimex... http://mnt.to/3FYV

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Clinical Trials MNT Clinical Trials

MNT Pancreatic Can MNT Pancreatic Can

Advertisement